Inflammatory Biomarkers as Predictors of Symptomatic Venous Thromboembolism in Hospitalized Patients with AECOPD: A Multicenter Cohort Study

Aim: Venous thromboembolism (VTE) risk significantly increases in patients with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD), which is characterized by an enhanced inflammatory response. This study aimed to evaluate the predictive value of inflammatory biomarkers for VTE i...

Full description

Saved in:
Bibliographic Details
Published inJournal of Atherosclerosis and Thrombosis Vol. 32; no. 4; pp. 439 - 457
Main Authors Zeng, Jiaxin, Feng, Jiaming, Luo, Yuanming, Wei, Hailong, Ge, Huiqing, Liu, Huiguo, Zhang, Jianchu, Li, Xianhua, Pan, Pinhua, Xie, XiuFang, Yi, Mengqiu, Cheng, Lina, Zhou, Hui, Zhang, Jiarui, Peng, Lige, Pu, Jiaqi, Chen, Xueqing, Yi, Qun, Zhou, Haixia, On behalf of the MAGNET AECOPD Registry Investigators
Format Journal Article
LanguageEnglish
Published Japan Japan Atherosclerosis Society 01.04.2025
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Aim: Venous thromboembolism (VTE) risk significantly increases in patients with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD), which is characterized by an enhanced inflammatory response. This study aimed to evaluate the predictive value of inflammatory biomarkers for VTE in AECOPD.Methods: A prospective, multicenter study was conducted to include patients hospitalized for AECOPD. Inflammatory biomarkers on admission were compared between the patients who developed VTE during hospitalization and the patients without VTE. A logistic regression analysis was used to identify inflammatory biomarkers with an independently predictive value.Results: Among the 13,531 AECOPD inpatients, 405 (2.99%) developed VTE during hospitalization. Patients who developed VTE had higher levels of inflammatory biomarkers, including the white blood cell count, neutrophil percentage, systemic immune/inflammatory index, neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio, C-reactive protein (CRP), procalcitonin (PCT), and lactate dehydrogenase (LDH), and lower lymphocyte and eosinophil ratios (ESOR), platelet, and albumin (p all <0.05). NLR, LDH, CRP, PCT, and ESOR were identified as independent predictors of VTE (odds ratios (ORs) were 2.22, 1.95, 1.64, 1.59, and 1.37, respectively). The incidence of VTE increased with increasing NLR, LDH, CRP, and PCT quartiles, and a decreasing ESOR quartile. Among them, NLR and LDH had predictive capabilities for VTE that were comparable to the widely used Padua and IMPROVE scores.Conclusion: Easily available inflammatory parameters, such as NLR and LDH, can identify AECOPD patients at increased risk for VTE who may therefore be candidates for thromboprophylaxis.
AbstractList Aim: Venous thromboembolism (VTE) risk significantly increases in patients with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD), which is characterized by an enhanced inflammatory response. This study aimed to evaluate the predictive value of inflammatory biomarkers for VTE in AECOPD. Methods: A prospective, multicenter study was conducted to include patients hospitalized for AECOPD. Inflammatory biomarkers on admission were compared between the patients who developed VTE during hospitalization and the patients without VTE. A logistic regression analysis was used to identify inflammatory biomarkers with an independently predictive value. Results: Among the 13,531 AECOPD inpatients, 405 (2.99%) developed VTE during hospitalization. Patients who developed VTE had higher levels of inflammatory biomarkers, including the white blood cell count, neutrophil percentage, systemic immune/inflammatory index, neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio, C-reactive protein (CRP), procalcitonin (PCT), and lactate dehydrogenase (LDH), and lower lymphocyte and eosinophil ratios (ESOR), platelet, and albumin ( p all <0.05). NLR, LDH, CRP, PCT, and ESOR were identified as independent predictors of VTE (odds ratios (ORs) were 2.22, 1.95, 1.64, 1.59, and 1.37, respectively). The incidence of VTE increased with increasing NLR, LDH, CRP, and PCT quartiles, and a decreasing ESOR quartile. Among them, NLR and LDH had predictive capabilities for VTE that were comparable to the widely used Padua and IMPROVE scores. Conclusion: Easily available inflammatory parameters, such as NLR and LDH, can identify AECOPD patients at increased risk for VTE who may therefore be candidates for thromboprophylaxis.
Venous thromboembolism (VTE) risk significantly increases in patients with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD), which is characterized by an enhanced inflammatory response. This study aimed to evaluate the predictive value of inflammatory biomarkers for VTE in AECOPD. A prospective, multicenter study was conducted to include patients hospitalized for AECOPD. Inflammatory biomarkers on admission were compared between the patients who developed VTE during hospitalization and the patients without VTE. A logistic regression analysis was used to identify inflammatory biomarkers with an independently predictive value. Among the 13,531 AECOPD inpatients, 405 (2.99%) developed VTE during hospitalization. Patients who developed VTE had higher levels of inflammatory biomarkers, including the white blood cell count, neutrophil percentage, systemic immune/inflammatory index, neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio, C-reactive protein (CRP), procalcitonin (PCT), and lactate dehydrogenase (LDH), and lower lymphocyte and eosinophil ratios (ESOR), platelet, and albumin (p all <0.05). NLR, LDH, CRP, PCT, and ESOR were identified as independent predictors of VTE (odds ratios (ORs) were 2.22, 1.95, 1.64, 1.59, and 1.37, respectively). The incidence of VTE increased with increasing NLR, LDH, CRP, and PCT quartiles, and a decreasing ESOR quartile. Among them, NLR and LDH had predictive capabilities for VTE that were comparable to the widely used Padua and IMPROVE scores. Easily available inflammatory parameters, such as NLR and LDH, can identify AECOPD patients at increased risk for VTE who may therefore be candidates for thromboprophylaxis.
Venous thromboembolism (VTE) risk significantly increases in patients with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD), which is characterized by an enhanced inflammatory response. This study aimed to evaluate the predictive value of inflammatory biomarkers for VTE in AECOPD.AIMVenous thromboembolism (VTE) risk significantly increases in patients with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD), which is characterized by an enhanced inflammatory response. This study aimed to evaluate the predictive value of inflammatory biomarkers for VTE in AECOPD.A prospective, multicenter study was conducted to include patients hospitalized for AECOPD. Inflammatory biomarkers on admission were compared between the patients who developed VTE during hospitalization and the patients without VTE. A logistic regression analysis was used to identify inflammatory biomarkers with an independently predictive value.METHODSA prospective, multicenter study was conducted to include patients hospitalized for AECOPD. Inflammatory biomarkers on admission were compared between the patients who developed VTE during hospitalization and the patients without VTE. A logistic regression analysis was used to identify inflammatory biomarkers with an independently predictive value.Among the 13,531 AECOPD inpatients, 405 (2.99%) developed VTE during hospitalization. Patients who developed VTE had higher levels of inflammatory biomarkers, including the white blood cell count, neutrophil percentage, systemic immune/inflammatory index, neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio, C-reactive protein (CRP), procalcitonin (PCT), and lactate dehydrogenase (LDH), and lower lymphocyte and eosinophil ratios (ESOR), platelet, and albumin (p all <0.05). NLR, LDH, CRP, PCT, and ESOR were identified as independent predictors of VTE (odds ratios (ORs) were 2.22, 1.95, 1.64, 1.59, and 1.37, respectively). The incidence of VTE increased with increasing NLR, LDH, CRP, and PCT quartiles, and a decreasing ESOR quartile. Among them, NLR and LDH had predictive capabilities for VTE that were comparable to the widely used Padua and IMPROVE scores.RESULTSAmong the 13,531 AECOPD inpatients, 405 (2.99%) developed VTE during hospitalization. Patients who developed VTE had higher levels of inflammatory biomarkers, including the white blood cell count, neutrophil percentage, systemic immune/inflammatory index, neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio, C-reactive protein (CRP), procalcitonin (PCT), and lactate dehydrogenase (LDH), and lower lymphocyte and eosinophil ratios (ESOR), platelet, and albumin (p all <0.05). NLR, LDH, CRP, PCT, and ESOR were identified as independent predictors of VTE (odds ratios (ORs) were 2.22, 1.95, 1.64, 1.59, and 1.37, respectively). The incidence of VTE increased with increasing NLR, LDH, CRP, and PCT quartiles, and a decreasing ESOR quartile. Among them, NLR and LDH had predictive capabilities for VTE that were comparable to the widely used Padua and IMPROVE scores.Easily available inflammatory parameters, such as NLR and LDH, can identify AECOPD patients at increased risk for VTE who may therefore be candidates for thromboprophylaxis.CONCLUSIONEasily available inflammatory parameters, such as NLR and LDH, can identify AECOPD patients at increased risk for VTE who may therefore be candidates for thromboprophylaxis.
Aim: Venous thromboembolism (VTE) risk significantly increases in patients with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD), which is characterized by an enhanced inflammatory response. This study aimed to evaluate the predictive value of inflammatory biomarkers for VTE in AECOPD.Methods: A prospective, multicenter study was conducted to include patients hospitalized for AECOPD. Inflammatory biomarkers on admission were compared between the patients who developed VTE during hospitalization and the patients without VTE. A logistic regression analysis was used to identify inflammatory biomarkers with an independently predictive value.Results: Among the 13,531 AECOPD inpatients, 405 (2.99%) developed VTE during hospitalization. Patients who developed VTE had higher levels of inflammatory biomarkers, including the white blood cell count, neutrophil percentage, systemic immune/inflammatory index, neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio, C-reactive protein (CRP), procalcitonin (PCT), and lactate dehydrogenase (LDH), and lower lymphocyte and eosinophil ratios (ESOR), platelet, and albumin (p all <0.05). NLR, LDH, CRP, PCT, and ESOR were identified as independent predictors of VTE (odds ratios (ORs) were 2.22, 1.95, 1.64, 1.59, and 1.37, respectively). The incidence of VTE increased with increasing NLR, LDH, CRP, and PCT quartiles, and a decreasing ESOR quartile. Among them, NLR and LDH had predictive capabilities for VTE that were comparable to the widely used Padua and IMPROVE scores.Conclusion: Easily available inflammatory parameters, such as NLR and LDH, can identify AECOPD patients at increased risk for VTE who may therefore be candidates for thromboprophylaxis.
ArticleNumber 65177
Author Chen, Xueqing
Feng, Jiaming
Zhang, Jianchu
Yi, Mengqiu
Zhou, Hui
Li, Xianhua
Zeng, Jiaxin
Luo, Yuanming
Ge, Huiqing
Peng, Lige
On behalf of the MAGNET AECOPD Registry Investigators
Cheng, Lina
Xie, XiuFang
Liu, Huiguo
Zhou, Haixia
Zhang, Jiarui
Yi, Qun
Pu, Jiaqi
Pan, Pinhua
Wei, Hailong
Author_xml – sequence: 1
  fullname: Zeng, Jiaxin
  organization: Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University
– sequence: 2
  fullname: Feng, Jiaming
  organization: West China School of Medicine, West China Hospital, Sichuan University
– sequence: 3
  fullname: Luo, Yuanming
  organization: State Key Laboratory of Respiratory Disease, Guangzhou Medical University
– sequence: 4
  fullname: Wei, Hailong
  organization: Department of Respiratory and Critical Care Medicine, People's Hospital of Leshan
– sequence: 5
  fullname: Ge, Huiqing
  organization: Department of Respiratory and Critical Care Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
– sequence: 6
  fullname: Liu, Huiguo
  organization: Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
– sequence: 7
  fullname: Zhang, Jianchu
  organization: Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
– sequence: 8
  fullname: Li, Xianhua
  organization: Department of Respiratory and Critical Care Medicine, the First People's Hospital of Neijiang City
– sequence: 9
  fullname: Pan, Pinhua
  organization: Department of Respiratory and Critical Care Medicine, Xiangya Hospital, Central South University
– sequence: 10
  fullname: Xie, XiuFang
  organization: Department of Respiratory and Critical Care Medicine, the First People's Hospital of Neijiang City
– sequence: 11
  fullname: Yi, Mengqiu
  organization: Department of Emergency, First People's Hospital of Jiujiang
– sequence: 12
  fullname: Cheng, Lina
  organization: Department of Emergency, First People's Hospital of Jiujiang
– sequence: 13
  fullname: Zhou, Hui
  organization: Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Chengdu University
– sequence: 14
  fullname: Zhang, Jiarui
  organization: Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University
– sequence: 15
  fullname: Peng, Lige
  organization: Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University
– sequence: 16
  fullname: Pu, Jiaqi
  organization: Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University
– sequence: 17
  fullname: Chen, Xueqing
  organization: Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University
– sequence: 18
  fullname: Yi, Qun
  organization: Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University
– sequence: 19
  fullname: Zhou, Haixia
  organization: Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University
– sequence: 20
  fullname: On behalf of the MAGNET AECOPD Registry Investigators
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39477518$$D View this record in MEDLINE/PubMed
BookMark eNpVkU1vEzEQhi1URD_gwB9APsIhZf2xtssFhVBopaJGauFq2d7ZrsPuOtheUPgN_GictAQ42B75ffzOeOYYHYxhBISek-q0rmvyemXyqaiJlI_QEVGqmjEl2UGJGS8xl-oQHae0qirG6po-QYfsjEtZE3WEfl2ObW-GweQQN_idD4OJXyEmbBJeRmi8K0LCocU3m2Gdi5y9w19gDFPCt10Mgw1QVu_TgP2IL0Ja-2x6_xMavCwwjDnhHz53eH6-uF6-f4Pn-NPUF5eiQMSL0IWY8U2ems1T9Lg1fYJnD-cJ-vzh_HZxMbu6_ni5mF_NHBdVnqkWGsKkcK2FChi1XBDaEMk5cdYoXm6FNZYyQoXgSrmKs5YUyNqWciPYCXp777ue7ADNtpJoer2Ovvx-o4Px-n9l9J2-C981IWeS1ZQXh5cPDjF8myBlPfjkoO_NCKUzuqSmgknGt-iLf5Pts_yZQQFe3QMuhpQitHuEVHo7X13mq3fz_Vv5KmVzB3vSxNLQHnYko5pvt92LveI6EzWM7Df94rHp
Cites_doi 10.3324/haematol.2016.142471
10.1093/jalm/jfab094
10.1002/ame2.12277
10.1016/j.ejim.2020.05.006
10.1186/s12879-024-09205-3
10.1186/s12890-024-02948-4
10.1111/crj.12959
10.7326/0003-4819-155-9-201111010-00008
10.1186/s12959-022-00381-3
10.1378/chest.11-2296
10.1016/j.amjmed.2015.10.027
10.1160/TH11-09-0611
10.1002/jhm.888
10.1159/000496914
10.1016/j.pupt.2006.04.004
10.1111/crj.12131
10.1055/a-1693-0063
10.2147/JIR.S327014
10.3233/CH-221664
10.1016/j.ijbiomac.2021.06.140
10.1177/10760296221130061
10.3390/ph16091254
10.1378/chest.06-2993
10.1097/MJT.0b013e31826910dd
10.1046/j.1365-2141.2001.03061.x
10.1159/000335904
10.1055/s-0042-1748193
10.3390/jcm10102061
10.1186/s40364-020-00207-2
10.1111/j.1538-7836.2007.02468.x
10.1111/aor.12943
10.4187/respcare.06661
10.3389/fimmu.2018.01351
10.1164/rccm.202301-0106PP
10.2147/COPD.S410954
10.1590/S1806-37132014000100006
10.1016/j.thromres.2003.12.003
10.1001/jama.2020.23567
10.2147/COPD.S396311
10.1007/PL00000237
10.1182/blood.2019004781
10.1378/chest.10-1944
10.1111/j.1538-7836.2010.04044.x
10.1016/j.jvsv.2022.05.003
10.1038/s41598-020-65128-4
10.1016/S0140-6736(08)60202-0
10.17219/acem/76262
10.1016/j.chest.2018.09.020
ContentType Journal Article
Copyright This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.
2025 Japan Atherosclerosis Society 2025
Copyright_xml – notice: This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.
– notice: 2025 Japan Atherosclerosis Society 2025
CorporateAuthor On behalf of the MAGNET AECOPD Registry Investigators
MAGNET AECOPD Registry Investigators
CorporateAuthor_xml – name: On behalf of the MAGNET AECOPD Registry Investigators
– name: MAGNET AECOPD Registry Investigators
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.5551/jat.65177
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1880-3873
EndPage 457
ExternalDocumentID PMC11973524
39477518
10_5551_jat_65177
article_jat_32_4_32_65177_article_char_en
Genre Multicenter Study
Journal Article
GroupedDBID ---
.55
29J
2WC
53G
5GY
5VS
ACGFO
ADBBV
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
DIK
DU5
E3Z
F5P
GX1
HYE
JMI
JSF
JSH
KQ8
OK1
P6G
RJT
RNS
RPM
RZJ
TR2
X7M
AAFWJ
AAYXX
CITATION
OVT
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c460t-8fed1376cfbe0e32b4612d17441cba84be06bab231266488c043f1461bbf24a63
ISSN 1340-3478
1880-3873
IngestDate Thu Aug 21 18:37:08 EDT 2025
Fri Jul 11 16:11:56 EDT 2025
Wed Jul 02 01:57:09 EDT 2025
Tue Jul 01 05:14:00 EDT 2025
Thu May 08 13:50:29 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 4
Keywords Inflammatory biomarkers
Acute exacerbation of chronic obstructive pulmonary disease
Venous thromboembolism
Language English
License This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.http://creativecommons.org/licenses/by-nc-sa/4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c460t-8fed1376cfbe0e32b4612d17441cba84be06bab231266488c043f1461bbf24a63
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
On behalf of the MAGNET AECOPD Registry Investigators
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC11973524
PMID 39477518
PQID 3122637344
PQPubID 23479
PageCount 19
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_11973524
proquest_miscellaneous_3122637344
pubmed_primary_39477518
crossref_primary_10_5551_jat_65177
jstage_primary_article_jat_32_4_32_65177_article_char_en
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2025-Apr-01
PublicationDateYYYYMMDD 2025-04-01
PublicationDate_xml – month: 04
  year: 2025
  text: 2025-Apr-01
  day: 01
PublicationDecade 2020
PublicationPlace Japan
PublicationPlace_xml – name: Japan
PublicationTitle Journal of Atherosclerosis and Thrombosis
PublicationTitleAlternate JAT
PublicationYear 2025
Publisher Japan Atherosclerosis Society
Publisher_xml – name: Japan Atherosclerosis Society
References 29) Ristić L, Rančić M, Radović M, Cirić Z, Kutlešić Kurtović D: Pulmonary embolism in chronic hypoxemic patients with and without secondary polycythemia--analysis of risk factors in prospective clinical study. Med Glas (Zenica), 2013; 10: 258-265
18) Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Deslandes B, Huang W, Zayaruzny M, Emery L, Anderson FA, Jr.: Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet, 2008; 371: 387-394
22) Couturaud F, Bertoletti L, Pastre J, Roy PM, Le Mao R, Gagnadoux F, Paleiron N, Schmidt J, Sanchez O, De Magalhaes E, Kamara M, Hoffmann C, Bressollette L, Nonent M, Tromeur C, Salaun PY, Barillot S, Gatineau F, Mismetti P, Girard P, Lacut K, Lemarié CA, Meyer G, Leroyer C: Prevalence of Pulmonary Embolism Among Patients With COPD Hospitalized With Acutely Worsening Respiratory Symptoms. JAMA, 2021; 325: 59-68
33) Liu X, Jiao X, Gong X, Nie Q, Li Y, Zhen G, Cheng M, He J, Yuan Y, Yang Y: Prevalence, Risk Factor and Clinical Characteristics of Venous Thrombus Embolism in Patients with Acute Exacerbation of COPD: A Prospective Multicenter Study. Int J Chron Obstruct Pulmon Dis, 2023; 18: 907-917
36) Tichelaar YI, Kluin-Nelemans HJ, Meijer K: Infections and inflammatory diseases as risk factors for venous thrombosis. A systematic review. Thromb Haemost, 2012; 107: 827-837
20) Brown RA, Allegra L, Matera MG, Page CP, Cazzola M: Additional clinical benefit of enoxaparin in COPD patients receiving salmeterol and fluticasone propionate in combination. Pulm Pharmacol Ther, 2006; 19: 419-424
34) Righini M: Is it worth diagnosing and treating distal deep vein thrombosis? No. J Thromb Haemost, 2007; 5 Suppl 1: 55-59
4) Keramidas G, Gourgoulianis KI, Kotsiou OS: Venous Thromboembolic Disease in Chronic Inflammatory Lung Diseases: Knowns and Unknowns. J Clin Med, 2021; 10
25) Bahloul M, Chaari A, Tounsi A, Baccouche N, Abid H, Chtara K, Ben Hamida C, Ghadhoune H, Dammak H, Chelly H, Bouaziz M: Incidence and impact outcome of pulmonary embolism in critically ill patients with severe exacerbation of chronic obstructive pulmonary diseases. Clin Respir J, 2015; 9: 270-277
7) Otasevic V, Mihaljevic B, Milic N, Stanisavljevic D, Vukovic V, Tomic K, Fareed J, Antic D: Immune activation and inflammatory biomarkers as predictors of venous thromboembolism in lymphoma patients. Thromb J, 2022; 20: 20
19) Baser O, Liu X, Phatak H, Wang L, Mardekian J, Kawabata H, Petersel D, Hamilton M, Ramacciotti E: Venous thromboembolism prophylaxis and clinical consequences in medically ill patients. Am J Ther, 2013; 20: 132-142
39) Liu H, Guo N, Zheng Q, Zhang Q, Chen J, Cai Y, Luo Q, Xu Q, Chen X, Yang S, Zhang S: Association of interleukin-6, ferritin, and lactate dehydrogenase with venous thromboembolism in COVID-19: a systematic review and meta-analysis. BMC Infect Dis, 2024; 24: 324
41) McFadyen JD, Kiefer J, Braig D, Loseff-Silver J, Potempa LA, Eisenhardt SU, Peter K: Dissociation of C-Reactive Protein Localizes and Amplifies Inflammation: Evidence for a Direct Biological Role of C-Reactive Protein and Its Conformational Changes. Front Immunol, 2018; 9: 1351
26) Akpinar EE, Hoşgün D, Akpinar S, Ataç GK, Doğanay B, Gülhan M: Incidence of pulmonary embolism during COPD exacerbation. J Bras Pneumol, 2014; 40: 38-45
30) Lederle FA, Zylla D, MacDonald R, Wilt TJ: Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: a background review for an American College of Physicians Clinical Practice Guideline. Ann Intern Med, 2011; 155: 602-615
6) Xue J, Ma D, Jiang J, Liu Y: Diagnostic and Prognostic Value of Immune/Inflammation Biomarkers for Venous Thromboembolism: Is It Reliable for Clinical Practice? J Inflamm Res, 2021; 14: 5059-5077
45) Xu WJ, Wang S, Yuan P, Wang L, Huang JX, Jiang R: Arterial and venous thromboembolism risk associated with blood eosinophils: A systematic review and meta-analysis. Animal Model Exp Med, 2022; 5: 470-481
35) Kerr R, Stirling D, Ludlam CA: Interleukin 6 and haemostasis. Br J Haematol, 2001; 115: 3-12
1) Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2018; 392: 1736-1788
49) Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, Cook DJ, Balekian AA, Klein RC, Le H, Schulman S, Murad MH: Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012; 141: e195S-e226S
40) Li D, Wu Q, Liu S, Chen Y, Chen H, Ruan Y, Zhang Y: Lactic Dehydrogenase in the In Vitro Evaluation of Hemolytic Properties of Ventricular Assist Device. Artif Organs, 2017; 41: E274-e284
31) Grant PJ, Greene MT, Chopra V, Bernstein SJ, Hofer TP, Flanders SA: Assessing the Caprini Score for Risk Assessment of Venous Thromboembolism in Hospitalized Medical Patients. Am J Med, 2016; 129: 528-535
10) Sheinenzon A, Shehadeh M, Michelis R, Shaoul E, Ronen O: Serum albumin levels and inflammation. Int J Biol Macromol, 2021; 184: 857-862
27) Dentali F, Pomero F, Micco PD, La Regina M, Landini F, Mumoli N, Pieralli F, Giorgi-Pierfranceschi M, Re R, Vitale J, Fabbri LM, Fontanella A, Arioli D: Prevalence and risk factors for pulmonary embolism in patients with suspected acute exacerbation of COPD: a multi-center study. Eur J Intern Med, 2020; 80: 54-59
44) Wypasek E, Padjas A, Szymańska M, Plens K, Siedlar M, Undas A: Non-classical and intermediate monocytes in patients following venous thromboembolism: Links with inflammation. Adv Clin Exp Med, 2019; 28: 51-58
8) Hojker M, Tršan J, Tršan U, Gale A, Jerman A, Košuta D: Predictive value of inflammatory and coagulation biomarkers for venous thromboembolism in COVID-19 patients. Clin Hemorheol Microcirc, 2023; 83: 387-395
2) Agustí A, Celli BR, Criner GJ, Halpin D, Anzueto A, Barnes P, Bourbeau J, Han MK, Martinez FJ, Montes de Oca M, Mortimer K, Papi A, Pavord I, Roche N, Salvi S, Sin DD, Singh D, Stockley R, López Varela MV, Wedzicha JA, Vogelmeier CF: Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Am J Respir Crit Care Med, 2023; 207: 819-837
48) Feng K, Wang K, Zhou Y, Xue H, Wang F, Jin H, Zhao W: Non-Anticoagulant Activities of Low Molecular Weight Heparins-A Review. Pharmaceuticals (Basel), 2023; 16
13) Zhang J, Yi Q, Zhou C, Luo Y, Wei H, Ge H, Liu H, Zhang J, Li X, Xie X, Pan P, Yi M, Cheng L, Zhou H, Liu L, Aili A, Liu Y, Peng L, Pu J, Zhou H: Characteristics, treatments, in-hospital and long-term outcomes among inpatients with acute exacerbation of chronic obstructive pulmonary disease in China: sex differences in a large cohort study. BMC Pulm Med, 2024; 24: 125
17) Tapson VF, Decousus H, Pini M, Chong BH, Froehlich JB, Monreal M, Spyropoulos AC, Merli GJ, Zotz RB, Bergmann JF, Pavanello R, Turpie AG, Nakamura M, Piovella F, Kakkar AK, Spencer FA, Fitzgerald G, Anderson FA, Jr.: Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest, 2007; 132: 936-945
37) Pfeiler S, Stark K, Massberg S, Engelmann B: Propagation of thrombosis by neutrophils and extracellular nucleosome networks. Haematologica, 2017; 102: 206-213
28) Choi KJ, Cha SI, Shin KM, Lee J, Hwangbo Y, Yoo SS, Lee J, Lee SY, Kim CH, Park JY, Jung TH: Prevalence and predictors of pulmonary embolism in Korean patients with exacerbation of chronic obstructive pulmonary disease. Respiration, 2013; 85: 203-209
12) Zhou C, Yi Q, Ge H, Wei H, Liu H, Zhang J, Luo Y, Pan P, Zhang J, Peng L, Aili A, Liu Y, Wang M, Tang Y, Wang L, Zhong X, Wang Y, Zhou H: Validation of Risk Assessment Models Predicting Venous Thromboembolism in Inpatients with Acute Exacerbation Of Chronic Obstructive Pulmonary Disease: A Multicenter Cohort Study in China. Thromb Haemost, 2022; 122: 1177-1185
47) Wan MX, Zhang XW, Törkvist L, Thorlacius H: Low molecular weight heparin inhibits tumor necrosis factor alpha-induced leukocyte rolling. Inflamm Res, 2001; 50: 581-584
50) Thachil J, Favaloro EJ, Lippi G: D-dimers-"Normal" Levels versus Elevated Levels Due to a Range of Conditions, including "D-dimeritis," Inflammation, Thromboembolism, Disseminated Intravascular Coagulation, and COVID-19. Semin Thromb Hemost, 2022; 48: 672-679
16) Zhai Z, Kan Q, Li W, Qin X, Qu J, Shi Y, Xu R, Xu Y, Zhang Z, Wang C: VTE Risk Profiles and Prophylaxis in Medical and Surgical Inpatients: The Identification of Chinese Hospitalized Patients’ Risk Profile for Venous Thromboembolism (DissolVE-2)-A Cross-sectional Study. Chest, 2019; 155: 114-122
46) Pu J, Yi Q, Luo Y, Wei H, Ge H, Liu H, Li X, Zhang J, Pan P, Zhou H, Zhou C, Yi M, Cheng L, Liu L, Zhang J, Peng L, Aili A, Liu Y, Zhou H: Blood Eosinophils and Clinical Outcomes in Inpatients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Prospective Cohort Study. Int J Chron Obstruct Pulmon Dis, 2023; 18: 169-179
3) Ambrosetti M, Ageno W, Spanevello A, Salerno M, Pedretti RF: Prevalence and prevention of venous thromboembolism in patients with acute exacerbations of COPD. Thromb Res, 2003; 112: 203-207
38) Hu J, Cai Z, Zhou Y: The Association of Neutrophil-Lymphocyte Ratio with Venous Thromboembolism: A Systematic Review and Meta-Analysis. Clin Appl Thromb Hemost, 2022; 28: 10760296221130061
42) Heerink JS, Gemen E, Oudega R, Geersing GJ, Hopstaken R, Kusters R: Performance of C-Reactive Protein, Procalcitonin, TAT Complex, and Factor VIII in Addition to D-Dimer in the Exclusion of Venous Thromboembolism in Primary Care Patients. J Appl Lab Med, 2022; 7: 444-455
11) Elmoamly S, Mattar M, Yacoub MF, Afif A: Can Biomarkers of Coagulation, Platelet Activation, and Inflammation Predict Venous Thromboembolism in Patients with Haematological Malignancies? Acta Haemat
44
45
46
47
48
49
50
10
11
12
13
14
15
16
17
18
19
1
2
3
4
5
6
7
8
9
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
References_xml – reference: 49) Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, Cook DJ, Balekian AA, Klein RC, Le H, Schulman S, Murad MH: Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012; 141: e195S-e226S
– reference: 27) Dentali F, Pomero F, Micco PD, La Regina M, Landini F, Mumoli N, Pieralli F, Giorgi-Pierfranceschi M, Re R, Vitale J, Fabbri LM, Fontanella A, Arioli D: Prevalence and risk factors for pulmonary embolism in patients with suspected acute exacerbation of COPD: a multi-center study. Eur J Intern Med, 2020; 80: 54-59
– reference: 38) Hu J, Cai Z, Zhou Y: The Association of Neutrophil-Lymphocyte Ratio with Venous Thromboembolism: A Systematic Review and Meta-Analysis. Clin Appl Thromb Hemost, 2022; 28: 10760296221130061
– reference: 33) Liu X, Jiao X, Gong X, Nie Q, Li Y, Zhen G, Cheng M, He J, Yuan Y, Yang Y: Prevalence, Risk Factor and Clinical Characteristics of Venous Thrombus Embolism in Patients with Acute Exacerbation of COPD: A Prospective Multicenter Study. Int J Chron Obstruct Pulmon Dis, 2023; 18: 907-917
– reference: 50) Thachil J, Favaloro EJ, Lippi G: D-dimers-"Normal" Levels versus Elevated Levels Due to a Range of Conditions, including "D-dimeritis," Inflammation, Thromboembolism, Disseminated Intravascular Coagulation, and COVID-19. Semin Thromb Hemost, 2022; 48: 672-679
– reference: 30) Lederle FA, Zylla D, MacDonald R, Wilt TJ: Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: a background review for an American College of Physicians Clinical Practice Guideline. Ann Intern Med, 2011; 155: 602-615
– reference: 44) Wypasek E, Padjas A, Szymańska M, Plens K, Siedlar M, Undas A: Non-classical and intermediate monocytes in patients following venous thromboembolism: Links with inflammation. Adv Clin Exp Med, 2019; 28: 51-58
– reference: 14) Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M, De Bon E, Tormene D, Pagnan A, Prandoni P: A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost, 2010; 8: 2450-2457
– reference: 17) Tapson VF, Decousus H, Pini M, Chong BH, Froehlich JB, Monreal M, Spyropoulos AC, Merli GJ, Zotz RB, Bergmann JF, Pavanello R, Turpie AG, Nakamura M, Piovella F, Kakkar AK, Spencer FA, Fitzgerald G, Anderson FA, Jr.: Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest, 2007; 132: 936-945
– reference: 46) Pu J, Yi Q, Luo Y, Wei H, Ge H, Liu H, Li X, Zhang J, Pan P, Zhou H, Zhou C, Yi M, Cheng L, Liu L, Zhang J, Peng L, Aili A, Liu Y, Zhou H: Blood Eosinophils and Clinical Outcomes in Inpatients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Prospective Cohort Study. Int J Chron Obstruct Pulmon Dis, 2023; 18: 169-179
– reference: 5) Chen Y, Zhong H, Zhao Y, Luo X, Gao W: Role of platelet biomarkers in inflammatory response. Biomark Res, 2020; 8: 28
– reference: 4) Keramidas G, Gourgoulianis KI, Kotsiou OS: Venous Thromboembolic Disease in Chronic Inflammatory Lung Diseases: Knowns and Unknowns. J Clin Med, 2021; 10:
– reference: 11) Elmoamly S, Mattar M, Yacoub MF, Afif A: Can Biomarkers of Coagulation, Platelet Activation, and Inflammation Predict Venous Thromboembolism in Patients with Haematological Malignancies? Acta Haematol, 2019; 141: 245-253
– reference: 32) Rothberg MB, Lindenauer PK, Lahti M, Pekow PS, Selker HP: Risk factor model to predict venous thromboembolism in hospitalized medical patients. J Hosp Med, 2011; 6: 202-209
– reference: 24) Pang H, Wang L, Liu J, Wang S, Yang Y, Yang T, Wang C: The prevalence and risk factors of venous thromboembolism in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease. Clin Respir J, 2018; 12: 2573-2580
– reference: 19) Baser O, Liu X, Phatak H, Wang L, Mardekian J, Kawabata H, Petersel D, Hamilton M, Ramacciotti E: Venous thromboembolism prophylaxis and clinical consequences in medically ill patients. Am J Ther, 2013; 20: 132-142
– reference: 12) Zhou C, Yi Q, Ge H, Wei H, Liu H, Zhang J, Luo Y, Pan P, Zhang J, Peng L, Aili A, Liu Y, Wang M, Tang Y, Wang L, Zhong X, Wang Y, Zhou H: Validation of Risk Assessment Models Predicting Venous Thromboembolism in Inpatients with Acute Exacerbation Of Chronic Obstructive Pulmonary Disease: A Multicenter Cohort Study in China. Thromb Haemost, 2022; 122: 1177-1185
– reference: 8) Hojker M, Tršan J, Tršan U, Gale A, Jerman A, Košuta D: Predictive value of inflammatory and coagulation biomarkers for venous thromboembolism in COVID-19 patients. Clin Hemorheol Microcirc, 2023; 83: 387-395
– reference: 35) Kerr R, Stirling D, Ludlam CA: Interleukin 6 and haemostasis. Br J Haematol, 2001; 115: 3-12
– reference: 7) Otasevic V, Mihaljevic B, Milic N, Stanisavljevic D, Vukovic V, Tomic K, Fareed J, Antic D: Immune activation and inflammatory biomarkers as predictors of venous thromboembolism in lymphoma patients. Thromb J, 2022; 20: 20
– reference: 3) Ambrosetti M, Ageno W, Spanevello A, Salerno M, Pedretti RF: Prevalence and prevention of venous thromboembolism in patients with acute exacerbations of COPD. Thromb Res, 2003; 112: 203-207
– reference: 42) Heerink JS, Gemen E, Oudega R, Geersing GJ, Hopstaken R, Kusters R: Performance of C-Reactive Protein, Procalcitonin, TAT Complex, and Factor VIII in Addition to D-Dimer in the Exclusion of Venous Thromboembolism in Primary Care Patients. J Appl Lab Med, 2022; 7: 444-455
– reference: 1) Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2018; 392: 1736-1788
– reference: 2) Agustí A, Celli BR, Criner GJ, Halpin D, Anzueto A, Barnes P, Bourbeau J, Han MK, Martinez FJ, Montes de Oca M, Mortimer K, Papi A, Pavord I, Roche N, Salvi S, Sin DD, Singh D, Stockley R, López Varela MV, Wedzicha JA, Vogelmeier CF: Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Am J Respir Crit Care Med, 2023; 207: 819-837
– reference: 25) Bahloul M, Chaari A, Tounsi A, Baccouche N, Abid H, Chtara K, Ben Hamida C, Ghadhoune H, Dammak H, Chelly H, Bouaziz M: Incidence and impact outcome of pulmonary embolism in critically ill patients with severe exacerbation of chronic obstructive pulmonary diseases. Clin Respir J, 2015; 9: 270-277
– reference: 34) Righini M: Is it worth diagnosing and treating distal deep vein thrombosis? No. J Thromb Haemost, 2007; 5 Suppl 1: 55-59
– reference: 9) Maners J, Gill D, Pankratz N, Laffan MA, Wolberg AS, de Maat MPM, Ligthart S, Tang W, Ward-Caviness CK, Fornage M, Debette S, Dichgans M, McKnight B, Boerwinkle E, Smith NL, Morrison AC, Dehghan A, de Vries PS: A Mendelian randomization of γ’ and total fibrinogen levels in relation to venous thromboembolism and ischemic stroke. Blood, 2020; 136: 3062-3069
– reference: 6) Xue J, Ma D, Jiang J, Liu Y: Diagnostic and Prognostic Value of Immune/Inflammation Biomarkers for Venous Thromboembolism: Is It Reliable for Clinical Practice? J Inflamm Res, 2021; 14: 5059-5077
– reference: 16) Zhai Z, Kan Q, Li W, Qin X, Qu J, Shi Y, Xu R, Xu Y, Zhang Z, Wang C: VTE Risk Profiles and Prophylaxis in Medical and Surgical Inpatients: The Identification of Chinese Hospitalized Patients’ Risk Profile for Venous Thromboembolism (DissolVE-2)-A Cross-sectional Study. Chest, 2019; 155: 114-122
– reference: 31) Grant PJ, Greene MT, Chopra V, Bernstein SJ, Hofer TP, Flanders SA: Assessing the Caprini Score for Risk Assessment of Venous Thromboembolism in Hospitalized Medical Patients. Am J Med, 2016; 129: 528-535
– reference: 23) Hassen MF, Tilouche N, Jaoued O, Elatrous S: Incidence and Impact of Pulmonary Embolism During Severe COPD Exacerbation. Respir Care, 2019; 64: 1531-1536
– reference: 29) Ristić L, Rančić M, Radović M, Cirić Z, Kutlešić Kurtović D: Pulmonary embolism in chronic hypoxemic patients with and without secondary polycythemia--analysis of risk factors in prospective clinical study. Med Glas (Zenica), 2013; 10: 258-265
– reference: 41) McFadyen JD, Kiefer J, Braig D, Loseff-Silver J, Potempa LA, Eisenhardt SU, Peter K: Dissociation of C-Reactive Protein Localizes and Amplifies Inflammation: Evidence for a Direct Biological Role of C-Reactive Protein and Its Conformational Changes. Front Immunol, 2018; 9: 1351
– reference: 26) Akpinar EE, Hoşgün D, Akpinar S, Ataç GK, Doğanay B, Gülhan M: Incidence of pulmonary embolism during COPD exacerbation. J Bras Pneumol, 2014; 40: 38-45
– reference: 20) Brown RA, Allegra L, Matera MG, Page CP, Cazzola M: Additional clinical benefit of enoxaparin in COPD patients receiving salmeterol and fluticasone propionate in combination. Pulm Pharmacol Ther, 2006; 19: 419-424
– reference: 48) Feng K, Wang K, Zhou Y, Xue H, Wang F, Jin H, Zhao W: Non-Anticoagulant Activities of Low Molecular Weight Heparins-A Review. Pharmaceuticals (Basel), 2023; 16:
– reference: 39) Liu H, Guo N, Zheng Q, Zhang Q, Chen J, Cai Y, Luo Q, Xu Q, Chen X, Yang S, Zhang S: Association of interleukin-6, ferritin, and lactate dehydrogenase with venous thromboembolism in COVID-19: a systematic review and meta-analysis. BMC Infect Dis, 2024; 24: 324
– reference: 15) Spyropoulos AC, Anderson FA Jr, FitzGerald G, Decousus H, Pini M, Chong BH, Zotz RB, Bergmann JF, Tapson V, Froehlich JB, Monreal M, Merli GJ, Pavanello R, Turpie AGG, Nakamura M, Piovella F, Kakkar AK, Spencer FA; IMPROVE Investigators: Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest, 2011; 140: 706-714
– reference: 43) Liu Y, Meng X, Feng J, Zhou X, Zhu H: Hypereosinophilia with Concurrent Venous Thromboembolism: Clinical Features, Potential Risk Factors, and Short-term Outcomes in a Chinese Cohort. Sci Rep, 2020; 10: 8359
– reference: 22) Couturaud F, Bertoletti L, Pastre J, Roy PM, Le Mao R, Gagnadoux F, Paleiron N, Schmidt J, Sanchez O, De Magalhaes E, Kamara M, Hoffmann C, Bressollette L, Nonent M, Tromeur C, Salaun PY, Barillot S, Gatineau F, Mismetti P, Girard P, Lacut K, Lemarié CA, Meyer G, Leroyer C: Prevalence of Pulmonary Embolism Among Patients With COPD Hospitalized With Acutely Worsening Respiratory Symptoms. JAMA, 2021; 325: 59-68
– reference: 40) Li D, Wu Q, Liu S, Chen Y, Chen H, Ruan Y, Zhang Y: Lactic Dehydrogenase in the In Vitro Evaluation of Hemolytic Properties of Ventricular Assist Device. Artif Organs, 2017; 41: E274-e284
– reference: 28) Choi KJ, Cha SI, Shin KM, Lee J, Hwangbo Y, Yoo SS, Lee J, Lee SY, Kim CH, Park JY, Jung TH: Prevalence and predictors of pulmonary embolism in Korean patients with exacerbation of chronic obstructive pulmonary disease. Respiration, 2013; 85: 203-209
– reference: 10) Sheinenzon A, Shehadeh M, Michelis R, Shaoul E, Ronen O: Serum albumin levels and inflammation. Int J Biol Macromol, 2021; 184: 857-862
– reference: 13) Zhang J, Yi Q, Zhou C, Luo Y, Wei H, Ge H, Liu H, Zhang J, Li X, Xie X, Pan P, Yi M, Cheng L, Zhou H, Liu L, Aili A, Liu Y, Peng L, Pu J, Zhou H: Characteristics, treatments, in-hospital and long-term outcomes among inpatients with acute exacerbation of chronic obstructive pulmonary disease in China: sex differences in a large cohort study. BMC Pulm Med, 2024; 24: 125
– reference: 18) Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Deslandes B, Huang W, Zayaruzny M, Emery L, Anderson FA, Jr.: Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet, 2008; 371: 387-394
– reference: 21) Hayssen H, Cires-Drouet R, Englum B, Nguyen P, Sahoo S, Mayorga-Carlin M, Siddiqui T, Turner D, Yesha Y, Sorkin JD, Lal BK: Systematic review of venous thromboembolism risk categories derived from Caprini score. J Vasc Surg Venous Lymphat Disord, 2022; 10: 1401-1409.e1407
– reference: 47) Wan MX, Zhang XW, Törkvist L, Thorlacius H: Low molecular weight heparin inhibits tumor necrosis factor alpha-induced leukocyte rolling. Inflamm Res, 2001; 50: 581-584
– reference: 45) Xu WJ, Wang S, Yuan P, Wang L, Huang JX, Jiang R: Arterial and venous thromboembolism risk associated with blood eosinophils: A systematic review and meta-analysis. Animal Model Exp Med, 2022; 5: 470-481
– reference: 36) Tichelaar YI, Kluin-Nelemans HJ, Meijer K: Infections and inflammatory diseases as risk factors for venous thrombosis. A systematic review. Thromb Haemost, 2012; 107: 827-837
– reference: 37) Pfeiler S, Stark K, Massberg S, Engelmann B: Propagation of thrombosis by neutrophils and extracellular nucleosome networks. Haematologica, 2017; 102: 206-213
– ident: 37
  doi: 10.3324/haematol.2016.142471
– ident: 42
  doi: 10.1093/jalm/jfab094
– ident: 45
  doi: 10.1002/ame2.12277
– ident: 27
  doi: 10.1016/j.ejim.2020.05.006
– ident: 39
  doi: 10.1186/s12879-024-09205-3
– ident: 13
  doi: 10.1186/s12890-024-02948-4
– ident: 24
  doi: 10.1111/crj.12959
– ident: 30
  doi: 10.7326/0003-4819-155-9-201111010-00008
– ident: 7
  doi: 10.1186/s12959-022-00381-3
– ident: 49
  doi: 10.1378/chest.11-2296
– ident: 31
  doi: 10.1016/j.amjmed.2015.10.027
– ident: 36
  doi: 10.1160/TH11-09-0611
– ident: 32
  doi: 10.1002/jhm.888
– ident: 11
  doi: 10.1159/000496914
– ident: 1
– ident: 20
  doi: 10.1016/j.pupt.2006.04.004
– ident: 25
  doi: 10.1111/crj.12131
– ident: 12
  doi: 10.1055/a-1693-0063
– ident: 6
  doi: 10.2147/JIR.S327014
– ident: 8
  doi: 10.3233/CH-221664
– ident: 10
  doi: 10.1016/j.ijbiomac.2021.06.140
– ident: 38
  doi: 10.1177/10760296221130061
– ident: 48
  doi: 10.3390/ph16091254
– ident: 17
  doi: 10.1378/chest.06-2993
– ident: 19
  doi: 10.1097/MJT.0b013e31826910dd
– ident: 35
  doi: 10.1046/j.1365-2141.2001.03061.x
– ident: 28
  doi: 10.1159/000335904
– ident: 50
  doi: 10.1055/s-0042-1748193
– ident: 4
  doi: 10.3390/jcm10102061
– ident: 5
  doi: 10.1186/s40364-020-00207-2
– ident: 34
  doi: 10.1111/j.1538-7836.2007.02468.x
– ident: 40
  doi: 10.1111/aor.12943
– ident: 23
  doi: 10.4187/respcare.06661
– ident: 41
  doi: 10.3389/fimmu.2018.01351
– ident: 2
  doi: 10.1164/rccm.202301-0106PP
– ident: 33
  doi: 10.2147/COPD.S410954
– ident: 26
  doi: 10.1590/S1806-37132014000100006
– ident: 3
  doi: 10.1016/j.thromres.2003.12.003
– ident: 22
  doi: 10.1001/jama.2020.23567
– ident: 46
  doi: 10.2147/COPD.S396311
– ident: 47
  doi: 10.1007/PL00000237
– ident: 9
  doi: 10.1182/blood.2019004781
– ident: 15
  doi: 10.1378/chest.10-1944
– ident: 29
– ident: 14
  doi: 10.1111/j.1538-7836.2010.04044.x
– ident: 21
  doi: 10.1016/j.jvsv.2022.05.003
– ident: 43
  doi: 10.1038/s41598-020-65128-4
– ident: 18
  doi: 10.1016/S0140-6736(08)60202-0
– ident: 44
  doi: 10.17219/acem/76262
– ident: 16
  doi: 10.1016/j.chest.2018.09.020
SSID ssj0033552
Score 2.4027667
Snippet Aim: Venous thromboembolism (VTE) risk significantly increases in patients with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD), which...
Venous thromboembolism (VTE) risk significantly increases in patients with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD), which is...
Aim: Venous thromboembolism (VTE) risk significantly increases in patients with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD), which...
SourceID pubmedcentral
proquest
pubmed
crossref
jstage
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 439
SubjectTerms Acute exacerbation of chronic obstructive pulmonary disease
Aged
Biomarkers - blood
C-Reactive Protein - analysis
Female
Follow-Up Studies
Hospitalization
Humans
Inflammation - blood
Inflammatory biomarkers
Male
Middle Aged
Neutrophils
Original
Prognosis
Prospective Studies
Pulmonary Disease, Chronic Obstructive - blood
Pulmonary Disease, Chronic Obstructive - complications
Risk Factors
Venous thromboembolism
Venous Thromboembolism - blood
Venous Thromboembolism - diagnosis
Venous Thromboembolism - epidemiology
Venous Thromboembolism - etiology
Title Inflammatory Biomarkers as Predictors of Symptomatic Venous Thromboembolism in Hospitalized Patients with AECOPD: A Multicenter Cohort Study
URI https://www.jstage.jst.go.jp/article/jat/32/4/32_65177/_article/-char/en
https://www.ncbi.nlm.nih.gov/pubmed/39477518
https://www.proquest.com/docview/3122637344
https://pubmed.ncbi.nlm.nih.gov/PMC11973524
Volume 32
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Journal of Atherosclerosis and Thrombosis, 2025/04/01, Vol.32(4), pp.439-457
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELbKglZ7WfFcygIyiBtKaWM3abmVssuCVOihC4VLFDsODdokVZtKsL-Bf8kfYcZ2Hq32AHuoVU3dOM18nRl7XoS8cKO4x9Rw6MgojhzuqYET-oI7ceQDfoTrR9pjOvnonZ3zD_P-vNX604ha2hSiIy-vzCu5DleBBnzFLNn_4Gx1USDAe-AvjMBhGP-Jx--zGBiaGkf5myRPMdZmtcbeMdMVemB0Kx1MS_mVLovcVGf9bKqyzharPBW5gtcFNsrAmle2h0hyCVbo1BRctdlvo5Pxp-lbk8auc3YxqFOtQJwswH7X0Yhb_uGGnatNzHwNtw5jsrYhm3rxdVJZ9N-UDQ1Owp9JBdjTmpqWOhajhzb6gPfrJsya5C_KtOAOk4vcUu15httvhMFoXQM2QvZytHNrNoS1IagZB_3BTfufjjI0kEVYK5g1pXt9elofXWhRzU0RJav1uSmTvatQ-mBQ6kYGRcfr9_ytOfDMl6lGFhtyH91XtU6tIh2nkzE6asHM5TfITRf2Mthm4928ikNiYPBpl3z5g0z5K1z4VbXsAdkv19iyn279gC3Ed3XV7mg3yLdhNc1uk0MLAzoy2L1DWiq7S_YnNqDjHvndhDCtIUzDNa0hTPOYNiBMDYTpDoRpktEmhGkJYYoQpgbCr-mINgBMDYCpBvB9cn56MhufObZBiCO51y2cQayiHmhIGQvVVSBaONjrEeyxeU-KcMCB6olQwBYGzFDQVLLLWYyN7IWIXR567AHZy_JMPSSUARykC7trzOwWDI8huBxK1mdhPJChbJPn5WMPlqYOTAD7Z2RTAGwKNJvaZGAYUk2xokFPYW7AcdBTq08wuRJkWZs8K1kYgIBHr12YKXiWAdy86zGfcd4mR4al1eVLUMDCW8yuJmDx-O1PsmShi8iXqHx0_a8ek4P6D_yY7BWrjXoCJnohnmqI_wVaifMR
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Inflammatory+Biomarkers+as+Predictors+of+Symptomatic+Venous+Thromboembolism+in+Hospitalized+Patients+with+AECOPD%3A+A+Multicenter+Cohort+Study&rft.jtitle=Journal+of+atherosclerosis+and+thrombosis&rft.au=Zeng%2C+Jiaxin&rft.au=Feng%2C+Jiaming&rft.au=Luo%2C+Yuanming&rft.au=Wei%2C+Hailong&rft.date=2025-04-01&rft.pub=Japan+Atherosclerosis+Society&rft.issn=1340-3478&rft.eissn=1880-3873&rft.volume=32&rft.issue=4&rft.spage=439&rft.epage=457&rft_id=info:doi/10.5551%2Fjat.65177&rft_id=info%3Apmid%2F39477518&rft.externalDocID=PMC11973524
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1340-3478&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1340-3478&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1340-3478&client=summon